SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
___________________________________
SCHEDULE 13D
(Rule 13d-101)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO
RULE 13d-2(a)
(Amendment No. 2){1}
BIOSITE DIAGNOSTICS INCORPORATED
(Name of Issuer)
COMMON STOCK, PAR VALUE $0.01 PER SHARE
(Title of Class of Securities)
09094510
(CUSIP Number)
KLAUS H. JANDER, ESQ.
ROGERS & WELLS LLP
200 PARK AVENUE
NEW YORK, NEW YORK 10166
(212) 878-8000
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
MAY 6, 1998
(Date of Event Which Requires Filing of This Statement)
If the filing person has previously filed a statement on
Schedule 13G to report the acquisition that is the subject of this
Schedule 13D, and is filing this schedule because of Rule 13d-1(e),
13d-1(f) or 13d-1(g), check the following box <square>.
NOTE. Schedules filed in paper format shall include a
signed original and five copies of the schedule, including all
exhibits. See Rule 13d-7(b) for other parties to whom copies are to
be sent.
(Continued on following pages)
(Page 1 of 5 Pages)
__________________________
{1} The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which would
alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, SEE the
NOTES.)
<PAGE>
SCHEDULE 13D
CUSIP NO. 09094510 PAGE 2 OF 5 PAGES
<TABLE>
<CAPTION>
1 NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
Merck KGaA
<S> <C> <C> <C>
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (A) <square>
(B) <square>
3 SEC USE ONLY
4 SOURCE OF FUNDS*
OO
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E)
<square>
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Federal Republic of Germany
7 SOLE VOTING POWER
0
NUMBER OF
SHARES 8 SHARED VOTING POWER
BENEFICIALLY
OWNED BY 0
EACH 9 SOLE DISPOSITIVE POWER
REPORTING
PERSON 0
WITH 10 SHARED DISPOSITIVE POWER
0
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON <square>
0
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* <square>
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
0.0%
14 TYPE OF REPORTING PERSON*
CO
</TABLE>
*SEE INSTRUCTIONS BEFORE FILLING OUT!
<PAGE>
This Amendment No. 2 (this "Amendment") to the Statement on Schedule 13D,
dated February 14, 1997 ("Schedule 13D"), as amended by Amendment No. 1
thereto, dated March 7, 1997, is filed by Merck KGaA in connection with its
beneficial ownership of Common Stock, par value $0.01 per share, of Biosite
Diagnostics Incorporated, a Delaware corporation (the "Common Stock").
Schedule 13D is hereby amended as follows:
ITEM 4. PURPOSE OF TRANSACTION
Item 4 of the Schedule 13D is amended in its entirety to read as follows:
"Merck KGaA determined to dispose of all of the 1,187,667 shares of Common
Stock that it beneficially owned (representing approximately 9.22% of the
12,876,016 shares of Common Stock reported by the Issuer to be outstanding
as of February 28, 1998 in the Issuer's most recent annual report filed on
Form 10-K pursuant to the Securities Exchange Act of 1934, as amended).
Solely for the purpose of facilitating this disposition, Merck KGaA
transferred all of its Common Stock to its related company, E. Merck
Beteiligungen OHG, a German general partnership, effective as of April
21, 1998.
"The disposition of all Common Stock previously beneficially held by Merck
KGaA was completed on May 6, 1998."
ITEM 5. INTEREST IN SECURITIES OF THE ISSUER
Item 5 of the Schedule 13D is amended in its entirety to read as follows:
"As of the date of the filing of this Amendment, Merck KGaA is the
beneficial owner of 0 shares of Common Stock, representing 0.0% of the
total issued and outstanding shares of Common Stock.
"Solely for the purpose of facilitating the disposition of all of its
Common Stock, Merck KGaA transferred all of its shares to its related
company, E. Merck Beteiligungen OHG, a German general partnership,
effective as of April 21, 1998. In three separate open-market
transactions, E. Merck Beteiligungen OHG effected the sale of Common Stock
to unrelated third parties. On May 6, 1998, 1,130,000 shares of Common
Stock were sold at $13.50 per share for a total purchase price of
$15,255,000; on April 23, 1998, 10,000 shares of Common Stock were sold at
$15.00 per share for a total purchase price of $150,000; and on April 22,
1998, 47,667 shares of Common Stock were sold at $15.0625 per share, for a
total purchase price of $717,984.18.
"Merck KGaA ceased to be a beneficial owner of more than 5% of the Common
Stock on May 6, 1998."
PAGE 3 OF 5 PAGES
<PAGE>
ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH
RESPECT TO SECURITIES OF THE ISSUER.
Item 5 of the Schedule 13D is amended by the addition of the following
paragraph:
"Solely for the purpose of facilitating the disposition of all of its
Common Stock, Merck KGaA transferred all of its shares to its related
company, E. Merck Beteiligungen OHG, a German general partnership,
effective as of April 21, 1998. In three separate open-market
transactions, E. Merck Beteiligungen OHG effected the sale of Common Stock
to unrelated third parties. On May 6, 1998, 1,130,000 shares of Common
Stock were sold at $13.50 per share; on April 23, 1998, 10,000 shares of
Common Stock were sold at $15.00 per share; and on April 22, 1998, 47,667
shares of Common Stock were sold at $15.0625 per share."
PAGE 4 OF 5 PAGES
<PAGE>
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete
and correct.
Date: May 27, 1998
MERCK KGAA
By: /s/ Klaus-Peter Brandis
________________________________
Name: Klaus-Peter Brandis
Title: Director
